693 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Gilead (GILD) Stock Likely to Beat This Earnings Season http://www.zacks.com/stock/news/224485/gilead-gild-stock-likely-to-beat-this-earnings-season?cid=CS-ZC-FT-224485 Jul 21, 2016 - Gilead Sciences (GILD), which is set to report second-quarter 2016 results on Jul 25, delivered a negative earnings surprise of 1.65% last quarter.
Why Eli Lilly (LLY) Might Surprise This Earnings Season http://www.zacks.com/stock/news/224330/why-eli-lilly-lly-might-surprise-this-earnings-season?cid=CS-ZC-FT-224330 Jul 21, 2016 - Eli Lilly (LLY) looks poised to beat analyst estimates this earnings season, with a favorable Zacks Rank and an ESP in positive territory.
Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain? http://www.zacks.com/stock/news/224276/eli-lilly-lly-may-beat-q2-earnings-will-the-stock-gain?cid=CS-ZC-FT-224276 Jul 21, 2016 - The combination of Lilly's Zacks Rank #3 and +1.18% ESP makes us very confident in looking for a positive earnings beat on Jul 26.
Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint? http://www.zacks.com/stock/news/223578/biogen-biib-q2-earnings-will-the-stock-disappoint?cid=CS-ZC-FT-223578 Jul 15, 2016 - Will Tecfidera scrips and sales recover enough to boost Biogen's (BIIB) performance in the second quarter?
J&J (JNJ) May Beat Q2 Earnings: Will the Stock Gain? http://www.zacks.com/stock/news/223564/jj-jnj-may-beat-q2-earnings-will-the-stock-gain?cid=CS-ZC-FT-223564 Jul 15, 2016 - J&J (JNJ) has a pretty good track record and could beat estimates in the second quarter given the Zacks Rank #2 and +1.80% ESP.
Eli Lilly, Boehringer Collaborate for Metastatic Breast Cancer http://www.zacks.com/stock/news/223479/eli-lilly-boehringer-collaborate-for-metastatic-breast-cancer?cid=CS-ZC-FT-223479 Jul 14, 2016 - Eli Lilly (LLY) inked a clinical trial collaboration with Boehringer for the evaluation of abemaciclib-BI 836845 combination for metastatic breast cancer.
Eli Lilly & Co. (LLY) John C. Lechleiter on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3968278-eli-lilly-and-co-lly-john-c-lechleiter-q1-2016-results-earnings-call-transcript?source=feed_all_articles Apr 26, 2016 - Eli Lilly & Co. (NYSE:LLY)Q1 2016 Earnings CallApril 26, 2016 9:00 am ETExecutivesJohn C. Lechleiter - Chairman, President & Chief Executive OfficerPhilip Johnson - Vice President, Investor Relations,
Eli Lilly and (LLY) Q1 2016 Results - Earnings Call Webcast http://seekingalpha.com/article/3967325-eli-lilly-lly-q1-2016-results-earnings-call-webcast?source=feed_all_articles Apr 26, 2016 - Earnings Conference Call Start time: April 26, 2016 at 09:00 AM ET.The audio will stream live while the call is active and can be replayed upon its completion.
Shire's Non-Stimulant Intuniv Approved in Europe for ADHD http://www.zacks.com/stock/news/190995/shires-non-stimulant-intuniv-approved-in-europe-for-adhd?cid=CS-ZC-FT-190995 Sep 22, 2015 - Shire's (SHPG) once-daily, non-stimulant Intuniv received European approval for the treatment of attention deficit hyperactivity disorder in children and adolescents.
TG Therapeutics Up on FDA Consent for Leukemia Study http://www.zacks.com/stock/news/190649/tg-therapeutics-up-on-fda-consent-for-leukemia-study?cid=CS-ZC-FT-190649 Sep 18, 2015 - TG Therapeutics (TGTX) reached an agreement with the FDA related to a Special Protocol Assessment of a phase III study design for TG-1101 for chronic lymphocytic leukemia.

Pages: 1...6364656667686970

<<<Page 68>